Ovary

Australia-based Prima BioMed has received approval from the Federal Agency for Medicines and Health Products (FAMHP) of Belgium for its amended CAN-004 clinical trial design.

The company said that CAN-004 is a multicentre, randomised Phase II clinical trial of CVac for the maintenance treatment of epithelial ovarian cancer in remission.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Based on progression-free survival results from its randomised CAN-003 trial, the company announced significant updates to its CVac clinical development programme in November 2013.

In that trial, CVac, an autologous dendritic cell-based product, showed a strong trend of increased progression-free survival in ovarian cancer patients in remission after second line treatment, compared with patients who did not receive CVac.

A new group of 210 epithelial ovarian cancer patients in remission after second-line platinum-based chemotherapy will be enrolled in the CAN-004 trial.

See Also:

Around 76 patients in remission after first-line surgery and chemotherapy have previously been randomised onto the CAN-004 trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s primary endpoint will be overall survival (OS) and secondary endpoints will include progression-free survival (PFS), adverse events, and immune monitoring.

Prima CEO Matthew Lehman said the company is happy to have received approval for the CAN-004 protocol amendment in Belgium, and expects other regulators will soon follow.

"It is exciting that we will soon be able to re-start recruitment of the CVac clinical trial for ovarian cancer," Lehman added.

Prima develops personalised immunocellular therapeutic products for the treatment of cancer and leverages its technology and expertise to bring new treatment options to market for patients.

Image: The CVac trial will enrol a new group of 210 epithelial ovarian cancer patients. Photo courtesy of dream designs at freedigitalphotos.net.